Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab.

Although a statistical trend toward an increase in TTV load was calculated in the 30 mg/kg group (Day 0: 1.8 log 10 c/mL [IQR 0–2.3], Day 35: 1.9 log 10 c/mL [IQR 1.3–2.8]; p = 0.054, n = 6; Figure 3 ), the absolute differences in median TTV load were minimal in both groups (60 mg/kg group: Day 0: 2.0 log 10 c/mL [IQR 1.6–3.0], Day 35: 2.1 log 10 c/mL [IQR 1.7–4.8]; p = 0.522, n = 6; Figure 3 ).

also in 565 other papers

Administering multiple lower doses (30 mg/kg) also showed a trend toward TTV load increase in healthy volunteers (1.8 log 10 c/mL, 0–2.3 vs. 1.9, 1.3–2.8; p = 0.054) and a significant increase in transplant recipients (3.5 log 10 c/mL, 3.0–6.1 vs. 4.1, 3.5–6.4; p = 0.004).

also in 11,799 other papers